Wednesday 15 November | |
Alternative Income REIT PLC | AGM |
Ascent Resources PLC | GM re approval to issue 45 million shares |
CQS Natural Resources Growth & Income PLC | AGM |
European Opportunities Trust PLC | AGM |
Hays PLC | AGM |
Henderson Eurotrust PLC | AGM |
Northern Bear PLC | GM re tender offer |
Reach PLC | GM re proposed capital reduction |
Synergia Energy Ltd | AGM |
Zegona Communications PLC | GM re acquisition agreement |
Thursday 16 November | |
Close Brothers Group PLC | AGM |
Craneware PLC | AGM |
Critical Mineral Resources PLC | AGM |
Dunelm Group PLC | AGM |
Eagle Eye Solutions Group PLC | AGM |
JD Wetherspoon PLC | AGM |
Kier Group PLC | AGM |
Marble Point Loan Financing Ltd | AGM |
MJ Gleeson PLC | AGM |
Origin Enterprises PLC | AGM |
Ricardo PLC | AGM |
Smiths Group PLC | AGM |
Friday 17 November | |
Future Metals NL | AGM |
Red Rock Resources PLC | GM re allot equity securities |
Rockpool Acquisitions PLC | AGM |
Saietta Group PLC | GM re annual accounts and reappointment of auditors |
US Solar Fund PLC | GM re change of investment policy |
Monday 20 November | |
Hellenic Dynamics SA | GM re share subdivision and share reclassification |
McBride PLC | AGM |
Mountview Estates PLC | GM re re-election of directors |
Ondo InsurTech PLC | AGM |
Rainbow Rare Earths Ltd | AGM |
Seraphim Space Investment Trust PLC | AGM |
Tuesday 21 November | |
Berkeley Energia Ltd | AGM |
Currys PLC | GM re proposed disposal of Kotsovolos |
Custodian Property Income REIT PLC | GM re articles of association |
Physiomics PLC | AGM |
Starvest PLC | GM re cancellation of listing |
Trainline PLC | GM re capital reduction |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
IN BRIEF: Physiomics celebrates "substantial" contract with old client
Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large pharma" client, though doesn't specify whom the client is. The project, which is valued at GBP178,000, involves involves pharmacokinetic-pharmacodynamic modelling in the field of DNA damage and repair fields. It is designed to help inform clinical dose and scheduling decisions. Physiomics expects this work to be completed over the course of the next six months.
Read more